To test whether the resistance to ICB specifically resulted from the p16Ink4a/p19Arf loss, and to exclude other potential confounders, we generated RT2-cancer cells from another diseased mouse and deleted p16Ink4a/p19Arf (gCdkn2a) using CRISPR-Cas931. Here, CDKN2A is linked to cancer.